The first treatment decision in bladder cancer is whether the tumour has grown into the bladder muscle. Most cancers that have not reached the muscle are treated by removing the tumour through a scope, sometimes followed by medicine placed directly into the bladder. When cancer has reached the muscle, treatment with the aim of cure usually involves bladder removal with medicines before or after surgery, or a bladder-preserving combination of chemotherapy and radiation in selected patients. If the cancer has spread to distant organs, medicines that act throughout the body are usually the main treatment. [1–3]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
Two pathology reports can both say “high-grade urothelial carcinoma” and lead to very different treatment plans. High grade describes how aggressive the cells look under the microscope. The next question is how deeply the tumour has grown and whether the sample contained enough bladder muscle to tell. If you are seeking bladder cancer treatment in Delhi, bring the pathology report, the notes from your bladder procedure, and the original scan images. Together, they help determine what needs to happen next.
1. What are the symptoms and risk factors for bladder cancer?
The most common symptom is blood in the urine, which can appear pink, red, or brown and may come and go without pain. Some people have burning while passing urine, a frequent or urgent need to urinate, or symptoms that resemble a urinary infection. Visible blood in the urine deserves assessment even if it happens only once and then stops. Heavy bleeding with clots, dizziness, or an inability to pass urine needs urgent medical attention. [1–3]
Smoking is a major risk factor. Certain occupational exposures, including chemicals used in some dye, rubber, and manufacturing industries, can also increase risk. A history of pelvic radiotherapy or treatment with cyclophosphamide may be relevant. Bladder cancer can also occur in people without these exposures. [1–3]
2. How is bladder cancer diagnosed and staged?
Cystoscopy allows a urologist to look inside the bladder through a thin scope. If a tumour is found, a transurethral resection of bladder tumour (TURBT) is usually performed. The surgeon removes visible tumour through the urethra and sends tissue for examination. TURBT helps establish the diagnosis and can be the first treatment for cancer confined to the inner layers of the bladder. [1, 2]
Most bladder cancers are urothelial carcinomas. The pathologist also checks for uncommon subtypes or features that may change management, such as small-cell neuroendocrine cancer or certain aggressive variants of urothelial carcinoma. CT urography can help assess the urinary tract, and staging scans are used when muscle invasion or spread is suspected. Urine cytology may provide additional information, particularly when high-grade disease is suspected. [1–3]
| Finding | What it means |
|---|---|
| Ta | A papillary tumour growing from the bladder lining without invasion into the tissue beneath it. |
| Tis, or carcinoma in situ (CIS) | A flat, high-grade cancer confined to the lining. It may be difficult to see during routine cystoscopy. |
| T1 | The tumour has grown into the connective tissue beneath the lining. The bladder muscle is still free of invasion if it was adequately sampled. |
| T2 or deeper | The tumour has reached the bladder muscle. More advanced local stages can involve fat around the bladder or nearby organs. |
| Regional or distant spread | Cancer has reached regional lymph nodes or distant sites such as the lungs, liver, or bones. Scans help define the extent. |
The report should say whether detrusor muscle, also called muscularis propria, was present and whether it contained cancer. If the first resection was incomplete, the tumour is T1, or muscle is missing in a case where it is needed to assess depth, a repeat TURBT may be recommended. [1]
3. How is non-muscle-invasive bladder cancer treated?
Non-muscle-invasive bladder cancer (NMIBC) includes Ta, T1, and CIS. After TURBT, the team estimates two risks: the chance that the tumour will return in the bladder and the chance that it will progress into the muscle. Stage, grade, CIS, tumour size and number, and the history of previous recurrences can all affect the recommendation. [1]
| Risk group or situation | What the team usually discusses |
|---|---|
| Low risk | Complete TURBT and scheduled cystoscopy. A single dose of chemotherapy placed into the bladder soon after TURBT may reduce recurrence when it can be given safely. |
| Intermediate risk | A course of chemotherapy placed into the bladder or BCG, depending on the individual risk and treatment history. |
| High risk | Intravesical BCG, usually an initial course followed by maintenance, or early bladder removal in selected cases. |
| Very high risk or high-grade disease that meets criteria for being BCG-unresponsive | Early radical cystectomy is an important option. If surgery is unsuitable or declined, the team can discuss bladder-sparing treatments or clinical trials where available. |
Intravesical treatment means that the medicine is placed directly into the bladder through a catheter. BCG is a form of local immunotherapy. After treatment, scheduled cystoscopy remains important because bladder cancer can recur without obvious symptoms. The follow-up schedule depends on the original risk group and how the tumour responds. [1]
4. When is bladder removal recommended, and can the bladder be preserved?
For muscle-invasive bladder cancer without distant spread, one standard treatment with the aim of cure is radical cystectomy, which removes the bladder and regional lymph nodes. The team also plans a new route for urine before surgery. Common options include an ileal conduit, which drains into a bag on the abdomen, or a neobladder, an internal reservoir made from bowel for suitable patients. Each has different recovery and long-term care requirements. [2, 3]
When is treatment given before bladder surgery?
For eligible patients, cisplatin-based chemotherapy before surgery treats possible microscopic spread early and can improve outcomes. Kidney function, hearing, nerve symptoms, and overall fitness help determine whether cisplatin is suitable. For selected patients eligible for cisplatin and immunotherapy, gemcitabine and cisplatin with durvalumab before surgery, followed by durvalumab after surgery, is an evidence-based option. Approaches using enfortumab vedotin plus pembrolizumab around surgery may also be relevant, including when cisplatin is unsuitable. The applicable Indian prescribing indication, access, and individual suitability should be verified when discussing these regimens. [2, 4]
What does bladder-preserving treatment involve?
Trimodality therapy combines removal of as much visible tumour as possible by TURBT with radiation and chemotherapy given during radiation. It may be appropriate for selected patients after review by a urologist, radiation oncologist, and medical oncologist. A single tumour that can be substantially removed by TURBT, a bladder that works well, and the absence of extensive CIS or tumour-related blockage of the kidney drainage system can make bladder preservation more suitable. Close cystoscopy follow-up is essential. Bladder removal may still be needed if invasive cancer persists or returns. [2, 3]
5. How is metastatic bladder cancer treated?
For unresectable or metastatic urothelial cancer, treatment usually aims to control the cancer, relieve symptoms, and help patients live longer where possible. Enfortumab vedotin plus pembrolizumab is a first-line option for many eligible patients. Enfortumab vedotin delivers a cancer-killing drug through an antibody, while pembrolizumab is an immunotherapy. Skin reactions, nerve symptoms, blood sugar control, and immune-related side effects can influence whether this combination is suitable. [2, 3]
When platinum-based chemotherapy is chosen, patients whose cancer has shrunk or remained stable may be offered maintenance avelumab. If the cancer progresses, the next option depends on previous treatment, overall fitness, and tumour testing. For example, a susceptible FGFR3 alteration can make erdafitinib an option in an appropriate later-line setting. Supportive care can begin alongside cancer treatment, including help with pain, bleeding, or a blocked kidney. [2, 3]
What I look for clinically before recommending treatment
I start by checking whether the TURBT report answers the question about muscle invasion. In high-grade T1 disease, the quality of the first resection and the need for a repeat procedure can change the plan. In muscle-invasive disease, I want to know whether the patient is fit for cisplatin and whether both bladder removal and bladder preservation are reasonable. When both are options, I discuss the full course of each, including the type of urinary diversion or the cystoscopy schedule after chemoradiation.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| A low-risk tumour completely removed at TURBT | Whether a single bladder instillation is appropriate and when to repeat cystoscopy |
| High-grade T1 disease or a sample that cannot establish depth | Whether repeat TURBT is needed and how to assess the risk of progression |
| High-risk disease confined to the inner layers | BCG, its follow-up schedule, and whether early bladder removal should be considered |
| Muscle-invasive cancer without distant spread | Medicines around surgery, urinary diversion, and suitability for trimodality therapy |
| Unresectable or metastatic disease | First-line systemic treatment, biomarker testing, and symptom control |
What to bring to a bladder cancer consultation in Delhi
- Cystoscopy and TURBT operation notes, including dates and whether visible tumour remained.
- Pathology reports stating the subtype, grade, depth of invasion, and whether bladder muscle was present.
- CT urography, CT, or MRI reports and the original images.
- Recent creatinine, kidney function results, and records of any ureteric stent or kidney drainage procedure.
- Dates and details of previous BCG, bladder instillations, chemotherapy, immunotherapy, or radiation.
- A note of current bleeding, urinary symptoms, and questions about bladder preservation or urinary diversion.
Frequently asked questions
Does high-grade bladder cancer mean it has reached the muscle?
High grade describes how the cancer cells look. Depth of invasion is a separate finding. A high-grade tumour may still be confined to the lining or the tissue just beneath it. [1]
Why do I need a second TURBT if the tumour was already removed?
A repeat procedure can find residual cancer and clarify how deeply it has grown. This is especially important in T1 disease or when the original specimen lacked muscle needed for accurate staging. [1]
Can muscle-invasive bladder cancer be treated without removing the bladder?
Yes. Trimodality therapy can be given with the aim of cure in selected patients. Suitability depends on tumour features, bladder function, and the ability to attend close follow-up. [2, 3]
Does bladder removal always mean using an external urine bag?
An ileal conduit uses an external bag. Some patients are suitable for a neobladder or another type of urinary diversion. The choice depends on cancer extent, kidney function, overall health, and what the patient can manage day to day. [2]
Before treatment, ask your team to write down the stage, grade, and whether bladder muscle was adequately sampled. If muscle invasion is confirmed, ask whether bladder removal and bladder preservation are both reasonable in your case, and what treatment and follow-up each would involve.
This page is for general education. Individual treatment decisions require review of your pathology, imaging, kidney function, and overall health by your treating team.
Clinical references
- European Association of Urology. EAU Guidelines on Non-muscle-invasive Bladder Cancer. 2026.
- European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026.
- National Comprehensive Cancer Network. NCCN Guidelines for Patients: Bladder Cancer. 2026.
- US Food and Drug Administration. Approval of Pembrolizumab With Enfortumab Vedotin for Muscle-Invasive Bladder Cancer. July 2026.